Abiomed announces enrollment of first patient in landmark RECOVER IV trial for AMI cardiogenic shock

Abiomed, part of Johnson & Johnson MedTech, announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).

Air quality improvements belie rising racial and ethnic disparities in pollutant-related deaths, study finds

The U.S. is making progress in reducing the public health consequences of air pollutants and fine particulate matter. But these improvements have not benefited everyone

March 6, 2024

Exposure to styrene and ethylbenzene elevates diabetes risk

Type 2 diabetes mellitus (T2DM) is a critical public health issue, with its prevalence expected to rise sharply worldwide.

September 18, 2024

Merck’s $3B return to eye disease; J&J’s $1.25B tuck-in; Keytruda challenger steals #ASCO24 show; and more

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.